Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

St Jude Children's Research Hospital discovers mechanism for faulty protein disposal

St. Jude Childrens Research Hospital : 07 December, 2007  (Company News)
Researchers from St Jude Children's Research Hospital have discovered how myeloma cells dispose of defective or excess proteins and could lead to new cancer treatments.
The researchers identified key cellular components that carry out protein disposal, a finding that helps to explain how cancer drugs called proteasome inhibitors interfere with this process.

The discovery is important because the newly identified components of the protein disposal mechanism could be targets for novel cancer drugs designed to kill the cell by blocking disposal of defective proteins.

Myelomas are cancers of plasma cells, which are the ‘activated’ form of B lymphocytes - immune system cells that respond to infection by temporarily producing extremely large amounts of proteins called antibodies that attack the target. The rapidly multiplying cancer cells continually make large numbers of new antibodies, which increases the chance for errors in the production process, resulting in the accumulation of defective proteins that must be degraded.

'Proteasome inhibitors are currently being used to treat some types of cancer including multiple myelomas, although many aspects of this cellular process remain poorly understood,' said Linda Hendershot, PhD, a member of the St Jude Department of Genetics and Tumor Cell Biology, and the paper's senior author.

'The results of our study help to explain how the process works and how we might design ways to block it in myelomas,' said Yuki Okuda-Shimizu, PhD a postdoctoral fellow in Hendershot's laboratory who contributed significantly to the project.

The work was supported by the National Institutes of Health, a Cancer Center Support Grant and ALSAC.

A report on the work appears in the November 30 issue of Molecular Cell.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   Â© 2012 ProHealthServiceZone.com
Netgains Logo